Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXL-01 combined with nivolumab for advanced NSCLC refractory to immunotherapy
2023-505285-28-01Phase 2Authorised
- Sponsor
- CHU de Lille
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exl01 and nivolumab in non-small cell lung cancer (NSCLC), sponsored by CHU de Lille. Primary endpoint: Progression-free survival rate at 3 months. Planned start Apr 2024; status: authorised.
02
Drugs
exl01nivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-505285-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505285-28-01.